4.2 Article

Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing

Journal

PHARMACOGENOMICS
Volume 18, Issue 7, Pages 673-685

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2017-0033

Keywords

CYP2D6; CYP450-2D6; genotyping; long-read sequencing; pharmacogenetics; pharmacogenomics; Sanger sequencing; short-read sequencing

Funding

  1. National Institute of General Medical Sciences (NIGMS) of the NIH [K23GM104401]

Ask authors/readers for more resources

CYP2D6 is one of the most studied enzymes in the field of pharmacogenetics. The CYP2D6 gene is highly polymorphic with over 100 catalogued star ((star)) alleles, and clinical CYP2D6 testing is increasingly accessible and supported by practice guidelines. However, the degree of variation at the CYP2D6 locus and homology with its pseudogenes make interrogating CYP2D6 by short-read sequencing challenging. Moreover, accurate prediction of CYP2D6 metabolizer status necessitates analysis of duplicated alleles when an increased copy number is detected. These challenges have recently been overcome by long-read CYP2D6 sequencing; however, such platforms are not widely available. This review highlights the genomic complexities of CYP2D6, current sequencing methods and the evolution of CYP2D6 from allele discovery to clinical pharmacogenetic testing.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available